This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer

This study has been terminated.
(funding discontinued by sponsor)
Sponsor:
Collaborators:
University of Louisville
Novartis Pharmaceuticals
Information provided by (Responsible Party):
James Graham Brown Cancer Center
ClinicalTrials.gov Identifier:
NCT00265200
First received: December 12, 2005
Last updated: April 4, 2017
Last verified: April 2017
  Purpose
The purpose of this study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases due to lung cancer.

Condition Intervention Phase
Carcinoma, Non-Small Cell Lung Carcinoma, Small Cell Lung Metastases Drug: zoledronic acid Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Diagnostic
Official Title: Bone Metabolic Markers, TRAP, and Zometa's Effect on Bone Metastasis Due to Lung Cancer

Resource links provided by NLM:


Further study details as provided by James Graham Brown Cancer Center:

Primary Outcome Measures:
  • Average Percent Change From Baseline in TRAP Levels at 2 Weeks [ Time Frame: TRAP levels at Baseline and 2 weeks after first Zometa infusion ]
    Change was calculated as 100% (value at baseline minus value at 2 weeks)/value at baseline


Enrollment: 28
Study Start Date: February 2005
Study Completion Date: December 2010
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: zoledronic acid
3.0-4.0 mg by IV (in the vein), once a month for 6 months
Drug: zoledronic acid
3.0-4.0 mg by IV (in the vein), once a month for 6 months
Other Name: Zometa

Detailed Description:
The purpose of this research study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases. The blood test will look for a protein, called TRAP, which is released into the blood stream by the breakdown of bone. This study will compare the TRAP blood test with other blood tests for bone destruction.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • invasive lung cancer (small cell or non-small cell lung cancer)
  • osteolytic bone metastasis determined by clinical exam, bone scan/XR
  • age > 18 years

Exclusion Criteria:

  • concurrent malignancy with a second primary
  • renal failure (serum creatinine > 3mg/dl)
  • pregnancy
  • active rheumatoid arthritis
  • intolerance to zoledronic acid
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00265200

Locations
United States, Kentucky
James Graham Brown Cancer Center
Louisville, Kentucky, United States, 40202
Sponsors and Collaborators
James Graham Brown Cancer Center
University of Louisville
Novartis Pharmaceuticals
Investigators
Principal Investigator: Goetz H Kloecker, MD, MSPH James Graham Brown Cancer Center/ University of Louisville
  More Information

Additional Information:
Responsible Party: James Graham Brown Cancer Center
ClinicalTrials.gov Identifier: NCT00265200     History of Changes
Other Study ID Numbers: 565.04
BCC-LUN-04-002 ( Other Identifier: James Graham Brown Cancer Center Clinical Trials Office )
Study First Received: December 12, 2005
Results First Received: April 8, 2013
Last Updated: April 4, 2017

Keywords provided by James Graham Brown Cancer Center:
Zometa
bone metastasis
lung cancer
non-small cell lung cancer
small cell lung cancer
bone metabolic markers
tartrate resistant acid phosphatase

Additional relevant MeSH terms:
Carcinoma, Small Cell
Carcinoma
Lung Neoplasms
Neoplasm Metastasis
Neoplasms, Second Primary
Carcinoma, Non-Small-Cell Lung
Small Cell Lung Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Neoplastic Processes
Pathologic Processes
Carcinoma, Bronchogenic
Bronchial Neoplasms
Zoledronic acid
Diphosphonates
Bone Density Conservation Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 16, 2017